Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: A review

Current Pharmaceutical Design

Volumn 17, Issue 14, 2011, Pages 1323-1332

  Edwards, Steven M ^a   Kenna, George A ^a   Swift, Robert M ^a,b   Leggio, Lorenzo ^a,c  

^a BROWN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Alcohol dependence; Alcohol pharmacotherapy; Alcohol typology; Pharmacogenetics

Indexed keywords

ACAMPROSATE; ARIPIPRAZOLE; BACLOFEN; CANNABINOID RECEPTOR; CITALOPRAM; CORTICOTROPIN RELEASING FACTOR; DISULFIRAM; FLUOXETINE; GHRELIN; NALTREXONE; NEUROPEPTIDE Y; ONDANSETRON; PLACEBO; PRAZOSIN; SERTRALINE; SUBSTANCE P; TACHYKININ RECEPTOR; TOPIRAMATE;

ALCOHOL ABSTINENCE; ALCOHOLISM; ALLELE; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TOXICITY; MEDICAL RESEARCH; MULTICENTER STUDY (TOPIC); NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT;

ALCOHOLISM; ANIMALS; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; RISK FACTORS;

EID: 79960010839     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796150765     Document Type: Review

References (142)

1. World Health Organization Global Status Report on Alcohol. Geneva: World Health Organization; 2011
2. World Health Organization Global Status Report on Alcohol. Geneva: World Health Organization; 2006
3. O'Connor PG. Alcohol abuse and dependence. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007: chap 31.
4. th ed.; DSM-IV. Washington, D.C.; American Psychiatric Association 2000
5. Faingold CL, N'gouemo P, Riaz A. Ethanol and neurotransmitter interactions: from molecular to integrative effects. Prog Neurobiol 1998; 55: 509-35.
6. Koob GF, Roberts AJ, Schulteis G, et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 1998; 22: 3-9.
7. O'Malley SS, Carroll KM. Psychotherapeutic considerations in pharmacological trials. Alcohol Clin Exp Res 1996; 20(7 Suppl): 17A-22A.
8. Pettinati HM, Volpicelli JR, Pierce JD, O'Brien CP. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. Journal of Addictive Diseases 2000; 19(1): 71-83.
9. National Institute for Alcohol Abuse and Alcoholism. Helping patients who drink too much. A clinician's guide [guide on the internet]. Updated 2005 edition [cited 2011 Mar 3]. Available from: http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide 2005/clinicians_guide.htm.
10. Kranzler HR, van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25(9): 1335-41.
11. Swift, R. Emerging approaches to managing alcohol dependence. Am J Health Syst Pharm 2007; 64(5 Suppl 3): S12-22.
12. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 281: 1318-25.
13. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram Treatment of Alcoholism. A Veterans Administration cooperative study. JAMA 1986; 256(11): 1449-55.
14. Carroll KM, Nich C, Ball SA, McCance E, Frankforter TL, Rounsaville BJ. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addictions 2000; 95(9): 1335-49.
15. Chick J, Gough K, Falkowski W, et al. Disulfiram treatment of alcoholism. Br J Psychiatry 1992; 161: 84-9.
16. Eneanya DI, Bianchine JR, Duran DO, Andresen BD. The actions of metabolic fate of disulfiram. Annu Rev Pharmacol Toxicol 1981; 21: 575-96.
17. Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Subst Use Misuse 2006; 41: 1395-463.
18. Goldstein M, Anagnoste B, Lauber E, McKeregham MR. Inhibition of dopamine-beta-hydroxylase by disulfiram. Life Sci 1964; 3: 763-7.
19. Vaccari A, Saba PL, Ruiu S, Collu M, Devoto P. Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Toxicol Appl Pharmacol 1996; 139: 102-8.
20. Fuller RK, Gordis E. Does Disulfiram Have A Role In Alcoholism Treatment Today? Addiction 2004; 99(1): 21-4.
21. Berglund M. A better widget? Three lessons for improving addiction treatment from a meta-analytical study. Addiction 2005; 100: 742-50.
22. Krampe H, Ehrenreich H. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des 2010; 16(19): 2076-90.
23. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993; 18: 247-91.
24. Gessa GL, Muntoni F, Collu M, Vargiu L, Mereu G. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res 1985; 346: 201-3.
25. Benjamin D, Grant E, Pohorecky LA. Naltrexone reverses ethanolinduced dopamine release in the nucleus accumbens in awake, freely moving rates. Brain Res 1993; 621: 137-40.
26. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876-80.
27. O'Malley SS, Jaffe AJ, Chang G, Schottenfield RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992; 49: 881-7.
28. Krystal JH, Cramer JA, Krol WF, Gail F, Kirk MS, Rosenheck RA. Naltrexone in the Treatment of Alcohol Dependence. NEJM 2001; 345: 1734-9.
29. Bouza C, Angeles M, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systemic review. Addiction 2004; 99(7): 811-28.
30. Srisurapanont M, Jarusaraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. International Journal of Neuropsychopharmacology. 2005; 8: 1-14.
31. Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opiod antagonists for alcohol dependence. Cochrane Database Syst Rev 2010; 12: CD001867.
32. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60(1): 92-9.
33. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295(17): 2003-17.
34. Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001; 25: 1634-47.
35. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opiod receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28(8): 1546-52.
36. Anton RF, Oroszi G, O'Malley SS, et al. An evaluation of muopiod receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008; 65: 135-44.
37. Ray LA, Chin PF, Miotto K. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets 2010; 9(1): 13-22.
38. Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001; 25: 1634-47.
39. Weiss RD. Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction 2004; 99(11): 1382-92.
40. Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebocontrolled clinical trial. Alcohol Clin Exp Res 2004; 28: 1051-9.
41. Johnson BA, Ait-Daoud N, Aubin HJ, et al. A Pilot Evaluation of the Safety and Tolerability of Repeat Dose Administration of Long-Acting Injectable Naltrexone in Patients with Alcohol Dependence. Alcohol Clin Exp Res 2004; 28(9): 1356-61.
42. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293: 1617-25.
43. Garbutt JC. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des 2010; 16(19): 2091-7.
44. Samson HH, Harris RA. Neurobiology of alcohol abuse. Trends Pharmacolo Sci 1992; 13: 206-11.
45. Tsai G. Gastriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry 1995; 152: 332-40.
46. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995; 30: 239-47.
47. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo controlled study on alcohol dependence. Arch Gen Psychiatry 1996; 53: 673-80.
48. Pelc I, Verbanck P, LeBon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo controlled dose finding study. Br J Psychiatry 1997; 171: 73-7.
49. Mann K, Lehert P, Morgan MY. The Efficacy of Acamprosate in the Maintenance of Abstinence in Alcohol-Dependent Individuals: Results of a Meta-Analysis. Alcohol Clin Exp Res 2004; 28: 51-63.
50. Kiefer F, Witt SH, Frank J. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J 2010; [Epub ahead of print]
51. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006; 40: 383-93.
52. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000; 35: 587-93.
53. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 2000; 35(2): 202-9.
54. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; 8(9): CD004332.
55. Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 2005; 19(10): 873-96.
56. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361(9370): 1677-85.
57. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298: 1641-51.
58. Johnson BA, Rosenthal N, Capece JA, et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment. Arch Intern Med 2008; 168: 1188-99.
59. Kenna G, Lomastro T, Schiesl A, Leggio L, Swift R. Review of Topiramate: An antiepileptic for the Treatment of Alcohol Dependence. Current Drug Abuse Reviews 2009; 2: 135-42.
60. Swift RM. Topiramate for the treatment of alcohol dependence: initiating abstinence. Lancet 2003; 361(9370): 1666-7.
61. Miranda RJ, MacKillop J, Monti PM, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 2008; 32: 489-97.
62. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Topamax (Topiramate): Label Change-Risk for development of cleft lip and/or cleft palate in newborns. US Food and Drug Administration.3/4/2011.
63. Maccioni P, Carai MA, Kaupmann K, et al. Reduction of alcohol's reinforcing and motivational properties by the positive allosteric modulator of the GABA(B) receptor, BHF177, in alcoholpreferring rats. Alcohol Clin Exp Res 2009; 33: 1749-56.
64. Franklin, TR, Wang, Z, Sciortino N, et al. Modulation of resting brain cerebral blood flow by the GABA B agonist, baclofen: A longitudinal perfusion fMRI study. Drug and Alcohol Depend 2011; [Epub ahead of print].
65. Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37: 504-8.
66. Leggio L, Kenna GA, Swift R. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Prog Neuropsychpopharmacol Biol LPsychiatry 2008; 32: 1106-17.
67. Flannery BA, Garbutt JC, Cody MW, et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res 2004; 28: 1517-23.
68. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcoholdependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 1915-22.
69. Avanesyan A, Runyon BA. Utilization of baclofen in maintenance of alcohol abstinence in patients with alcoholic hepatitis in a reallife clinical setting. Hepatology 2010; 52: 1104A [AASLD abstract].
70. Garbutt, JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010; 34(11): 1849-57.
71. Flannery BA, Garbutt JC. Comparison of U.S. and Italian human baclofen trials: why the difference? Alcohol Clin Exp Res 2008; 32(suppl 1): 276A.
72. Garbutt, JC. The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat 2009; 36: S15-23.
73. Leggio L, Garbutt JC, Addolorato G. Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets 2010; 9(1): 33-44.
74. Addolorato G, Leggio L, Ferrulli A, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol-dependent subjects: secondary analysis of a randomized double-blind placebo controlled trial. Alcohol Alcohol 2011; [Epub ahead of print].
75. Szumlinski KK, Diab ME, Friedman R, Henze LM, Lominac KD, Bowers MS. Accumbens neurochemical adaptations produced by binge-like alcohol consumption. Psychopharmacology (Berl) 2007; 190(4): 415-31.
76. Kenna GA. Medications acting on the serotonergic system for the treatment of alcohol dependent patients. Curr Pharm Des 2010; 16(19): 2126-35.
77. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994; 18: 879-85.
78. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA 2000; 284: 963-971.
79. Johnson BA, Roache JD, Ait-Daoud N, Zanca NA, Velazquez M. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (Berl) 2002; 160(4): 408-13.
80. Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic Approach at the Serotonin Transporter Gene as a Method of Reducing the Severity of Alcohol Drinking. Am J Psychiatry 2011; 168(3): 265-75.
81. Kenna GA, Zywiak WH, McGeary JE, et al. A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res 2009; 33(2): 315-23.
82. Gulley JM, McNamara C, Barbera TJ, Ritz MC, George FR. Selective erotonin reuptake inhibitors: Effects of chronic treatment
83. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152: 391-7.
84. Pettinati HM, Volpicelli JR, Luck G, Kranzler HR, Rukstalis MR, Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 2001; 21(2): 143-53.
85. Kranzler HR, Armeli S, Tennen H, et al. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol 2011; 31(1): 22-30.
86. Naranjo CA, Bremner KE, Lanctôt KL. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 1995; 90: 87-99.
87. Kenna GA. Rationale for use of aripiprazole for alcohol dependence treatment. Drugs of the Future 2003; 28(12): 1227-35.
88. Kranzler HR, Covault J, Pierucci-Lagha A, et al. Effects of aripiprazole on subjective and physiological responses to alcohol. Alcohol Clin Exp Res 2008; 32(4): 573-9.
89. Voronin K, Randall P, Myrick H, Anton R. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. Alcohol Clin Exp Res 2008; 32(11): 1954-61.
90. Myrick H, Li X, Randall PK, Henderson S, Voronin K, Anton RF. The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol 2010; 30(4): 365-72.
91. Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 2008; 28(1): 5-12.
92. Martinotti G, Di Nicola M, Di Giannantonio M, Janiri L. Aripiprazole in the treatment of patients with alcohol dependence: a doubleblind, comparison trial vs. naltrexone. J Psychopharmacol 2009; 23(2): 123-9.
93. Kook GF. A role for brain stress systems in addiction. Neuron 2008; 59: 11-34.
94. Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 2005; 28: 403-450.
95. Ventura R, Alcaro A, Puglisi-Allegra S. Prefrontal cortical norepinephrine release is critical for morphine-induced reward, reinstatement and dopamine release in the nucleus accumbens. Cereb Cortex 2005; 15: 1877-86.
96. Koob GF. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 1999; 46: 1167-80.
97. Cecchi M, Khoshbouei H, Morilak DA. Modulatory effects of norepinephrine, acting on alpha 1 receptors in the central nucleus of the amygdala, on behavioral and neuroendocrine responses to acute immobilization stress. Neuropharmacology 2002; 43: 1139-47.
98. Mason BJ, Kocsis JH. Desipramine treatment of alcoholism. Psychopharmacol Bull 1991; 27: 155-61.
99. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996; 275: 761-7.
100. Walker BM, Rasmussen DD, Raskind MA, Koob GF. Alpha1- noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol. Alcohol 2008; 42: 91-7.
101. Rasmussen DD, Alexander LL, Raskind MA, Froehlich JC. The alpha1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. Alcohol Clin Exp Res 2009; 33: 264-72.
102. Simpson TL, Saxon AJ, Meredith CW, et al. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res 2009; 33: 255-63.
103. Leggio L, Cardone S, Ferrulli A, et al. Turning the clock ahead: potential preclinical and clinical neuropharmacological targets for alcohol dependence. Curr Pharm Des 2010; 16(19): 2159-18.
104. Colombo G, Orru'A, Lai P, et al. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. Mol Neurobiol 2007; 36(1): 102-12.
105. Roberto M, Cruz M, Bajo M, Siggins GR, Parsons LH, Schweitzer P. The Endocannabinoid System Tonically Regulates Inhibitory Transmission and Depresses the Effect of Ethanol in Central Amygdala. Neuropsychopharmacology 2010; 35(9): 1962-72.
106. Soyka M, Koller G, Schmidt P, et al. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 2008; 28(3):317-24.
107. George DT, Herion DW, Jones CL, et al. Rimonabant (SR141716) has no effect on alcohol selfadministration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology (Berl) 2010; 208(1): 37-44.
108. US Food and Drug Administration Advisory Committee, FDA briefing document: Zimulti (rimonabant) Tablets, 20 mg, FDA, Rockville (2007) http://www.fda.gov/OHRMS/DOCKETS/AC/07/briefing/2007- 4306b1-00-index.htm
109. Sinha R. How does stress increase risk of drug abuse and relapse? Psychophamacology 2001; 158: 343-59.
110. Clarke TK, Schumann G. Gene-environment interactions resulting in risk alcohol drinking behaviour are mediated by CRF and CRF1. Pharmacol Biochem Behav 2009; 93(3):230-6.
111. Clarke TK, Schumann G. Gene-environment interactions resulting in risk alcohol drinking behaviour are mediated by CRF and CRF1. Pharmacol Biochem Behav 2009; 93(3):230-6.
112. Olive MF, Koenig HN, Nannini MA, Hodge CW. Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. Pharmacol Biochem Behav 2002; 72(1-2): 213-20.
113. Treutlein J, Kissling C, Frank J, et al. Genetic association of the human corticotrophin releasing hormone receptor 1 (CRHR1) with binge drinking and alcohol intake patterns in two independent samples. Mol Psychiatry 2006; 11(6): 594-602.
114. Blomeyer D, Treutlein J, Esser G, Schmidt MH, Schumann G, Laucht M. Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use. Biol Psychiatry 2008; 63(2):146-51.
115. Stogner KA, Holmes PV. Neuropeptide-Y exerts antidepressantlike effects in the forced swim test in rats. Eur J Pharmacol 2000; 387(2):R9-10.
116. Thiele TE, Marsh DJ, Ste Marie L, Bernstein IL, Palmiter RD. Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature 1998; 396(6709): 366-9.
117. Zhang H, Sakharkar AJ, Shi G, Ugale R, Prakash A, Pandey SC. Neuropeptide y signaling in the central nucleus of amygdala regulates alcohol-drinking and anxiety-like behaviors of alcoholpreferring rats. Alcohol Clin Exp Res 2010; 34(3): 451-61.
118. Jerlhag E, Egecioglu E, Dickson SL, Andersson M, Svensson L, Engel JA. Ghrelin stimulates locomotor activity and accumbal dopamine-overflow via central cholinergic systems in mice: Implications for its involvement in brain reward. Addict Biol 2006; 11(1): 45-54.
119. Jerlhag E, Egecioglu E, Dickson SL, Douhan A, Svensson L, Engel JA. Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens. Addict Biol 2007; 12(1): 6-16.
120. Jerlhag E. Systemic administration of ghrelin induces conditioned place preference and stimulates accumbal dopamine. Addict Biol 2008; 13(3-4): 358-63.
121. Jerlhag E, Egecioglu E, Landgren S, et al. Requirement of central ghrelin signaling for alcohol reward. Proc Natl Acad Sci USA 2009; 106(27): 11318-23.
122. Leggio L, Ferrulli A, Cardone S, et al. Ghrelin system in alcoholdependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. Addiction Biology 2011; (in press).
123. Leggio L. Role of the ghrelin system in alcoholism: Acting on the growth hormone secretagogue receptor to treat alcohol-related diseases. Drug News Perspect 2010; 23(3): 157-66.
124. Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 2003; 24(11): 580-8.
125. George D, Gilman, J, Hersh J, et al. Neurokinin 1 receptor as a possible therapy for alcoholism. Science 2008; 319: 1536-9.
126. Thorsell A, Schank J, Singley E, Hunt S, Heilig M. Neurokinin-1 receptors (NK1R:s_, alcohol consumption, and alcohol reward in mice. Psychopharmacology 2010; 209: 103-11.
127. Seneviratne C, Ait-Daoud N, Ma J, Chen G, Johnson BA, Li M. Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence. Neuropsychopharmacology 2009; 34: 2442-9.
128. Leggio L, Kenna GA, Fenton M, Bonenfant E, Swift RM. Typologies of Alcohol Dependence. From Jellinek to Genetics and Beyond. Neuropsychol Rev 2009; 19(1): 115-29.
129. Jellinek EM. The Disease Concept of Alcoholism. New Brunswick: Hillhouse Press 1960.
130. Cloninger CR, Bohman M, Sigvardsson S. Inheritance of alcohol abuse. Cross-fostering analysis of adopted men. Archives of General Psychiatry 1981; 38: 861-8.
131. Babor TF, Hofmann MI, DelBoca FK, et al. (1992a). Types of alcoholics, I. Evidence for an empirically derived typology based on indicator of vulnerability and severity. Archives of General Psychiatry 1992; 49: 599-608.
132. Dahmen N, Volp M, Singer P, Hiemke C, Szegedi A. Tyrosine hydroxylase Val-81-Met polymorphism associated with early-onset alcoholism. Psychiatr Genet 2005; 15: 13-16.
133. Windle M, Scheidt D. Alcoholic Subtypes: are two sufficient? Addiction 2004; 99: 1508-19.
134. Lesch OM, Kefer J, Lentner S, et al. The course of alcoholism. Long-term prognosis in different subtypes. Forensic Science International 1988; 36: 121-38.
135. Kranzler HR, Edenberg HJ. Pharmacogenetics of alcohol and alcohol dependence treatment. Curr Pharm Des; 2010 16(19): 2141-8.
136. Ray LA, Bryan A, Mackillop J, McGeary J, Hesterberg K, Hutchison KE. The dopamine D Receptor (DRD4) gene exon III polymorphism, problematic alcohol use and novelty seeking: direct and mediated genetic effects. Addict Biol 2009; 14(2): 238-44.
137. Hutchison KE, McGeary J, Smolen A, Bryan A, Swift RM. The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychol 2002; 21(2): 139-46.
138. Hutchison KE, Wooden A, Swift RM, et al. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 2003; 28(10): 1882-8.
139. Hutchison KE, Ray L, Sandman E, Rutter MC, et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 2006; 31(6): 1310-7.
140. Mackillop J, Menges DP, McGeary JE, Lisman SA. Effects of craving and DRD4 VNTR genotype on the relative value of alcohol: an initial human laboratory study. Behav Brain Funct 2007; 3: 11.
141. McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr. Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res 2006; 30(8): 1288-96.
142. van den Wildenberg E, Janssen RG, Hutchison KE, van Breukelen GJ, Wiers RW. Polymorphisms of the dopamine D4 receptor gene (DRD4 VNTR) and cannabinoid CB1 receptor gene (CNR1) are not strongly related to cue-reactivity after alcohol exposure. Addict Biol 2007; 12(2): 210-20.